Kevin Gardner
Host, LifeSci Advisors
Replay available
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Q4 2023 earnings conference call, held 2024-02-29. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Ted White
President and Chief Executive Officer
Joe Bonacorso
Chief Commercial Officer
Terry Kohler
Chief Financial Officer
Stacey Koo
Analyst, TB Cohen
Oren Livnat
Analyst, H.C. Wainwright
Kim Dolliver
Analyst, Brookline Capital Markets
Chris Hayes
Chief Legal Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Verrica Pharmaceuticals Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:04.790 Good morning, ladies and gentlemen, and welcome to the Verica Pharmaceuticals fourth 00:00:04.790 -- 00:00:07.370 quarter and year-end 2023 00:00:07.370 -- 00:00:10.731 corporate update and earnings conference call. 00:00:10.731 -- 00:00:13.092 As a reminder, this conference is being recorded. 00:00:13.092 -- 00:00:19.013 I'll now turn the call over to our host, Kevin Gardner of LifeSci Advisors. 00:00:19.013 -- 00:00:21.613 You may begin your conference. 00:00:23.094 -- 00:00:28.155 Thank you, operator. Hello, everyone, and welcome to Verica Pharmaceuticals 00:00:28.155 -- 00:00:31.175 fourth quarter and year-end 00:00:31.657 -- 00:00:35.749 2023 Corporate Update and Earnings Conference Call. 00:00:35.749 -- 00:00:41.231 With me on the line this morning are Ted White, President and Chief Executive Officer 00:00:41.231 -- 00:00:43.332 of Verica Pharmaceuticals, 00:00:43.332 -- 00:00:48.493 Joe Bonaccorso, Chief Commercial Officer, Terry Kohler, Chief 00:00:48.493 -- 00:00:53.655 Financial Officer, Dr. Gary Goldenberg, Verica's Chief 00:00:53.655 -- 00:01:00.257 Medical Officer, and Chris Hayes, Verica's Chief Legal Officer. 00:01:00.931 -- 00:01:06.394 As a reminder during today's call, management will make forward-looking statements. 00:01:06.394 -- 00:01:11.517 These statements may include expectations related to the launch and 00:01:11.517 -- 00:01:17.421 commercialization of YCANT for the treatment of molluscum contagiosum 00:01:17.421 -- 00:01:22.464 in the United States, regulatory development, the development of Verica's 00:01:22.464 -- 00:01:24.265 product candidate, 00:01:24.265 -- 00:01:29.348 our expected cash runway, as well as overall business strategy 00:01:29.348 -- 00:01:31.892 and planned operations. 00:01:31.892 -...